RxSight Inc. (RXST)
26.61
-0.06 (-0.22%)
At close: Mar 28, 2025, 3:59 PM
26.42
-0.71%
After-hours: Mar 28, 2025, 06:04 PM EDT
-0.22% (1D)
| Bid | 25.56 |
| Market Cap | 1.08B |
| Revenue (ttm) | 150.52M |
| Net Income (ttm) | -27.55M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -37.48 |
| Forward PE | 236.09 |
| Analyst | Buy |
| Ask | 29.65 |
| Volume | 451,603 |
| Avg. Volume (20D) | 607,033 |
| Open | 26.39 |
| Previous Close | 26.67 |
| Day's Range | 26.25 - 26.65 |
| 52-Week Range | 24.09 - 66.54 |
| Beta | 1.22 |
About RXST
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment dev...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 30, 2021
Employees 498
Stock Exchange NASDAQ
Ticker Symbol RXST
Website https://www.rxsight.com
Analyst Forecast
According to 9 analyst ratings, the average rating for RXST stock is "Buy." The 12-month stock price forecast is $43, which is an increase of 61.59% from the latest price.
Stock ForecastsNext Earnings Release
RxSight Inc. is scheduled to release its earnings on May 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-8.11%
RxSight shares are trading lower after Stifel cut ...
Unlock content with
Pro Subscription
3 months ago
-11.86%
RxSight shares are trading lower after Stifel downgraded the stock from Buy to Hold and cut its price target from $65 to $40.
